Credit Suisse Ag 4 D Molecular Therapeutics, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 24,016 shares of FDMT stock, worth $144,336. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,016

Previous 22,326 7.57%

Holding current value

$144,336

Previous $452,000 69.25%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$17.03 - $35.87 $28,780 - $60,620	1,690 Added 7.57%	24,016 $765,000
Q4 2023 Feb 08, 2024	SELL	$9.76 - $21.25 $33,359 - $72,632	-3,418 Reduced 13.28%	22,326 $452,000
Q3 2023 Nov 13, 2023	SELL	$12.64 - $19.76 $112,154 - $175,330	-8,873 Reduced 25.63%	25,744 $327,000
Q2 2023 Aug 11, 2023	BUY	$15.16 - $23.26 $320,664 - $491,995	21,152 Added 157.09%	34,617 $625,000
Q1 2023 May 10, 2023	BUY	$15.45 - $23.19 $208,018 - $312,230	13,464 Added 1346400.0%	13,465 $231,000
Q4 2022 Feb 13, 2023	SELL	$6.85 - $25.46 $120,196 - $446,746	-17,547 Reduced 99.99%	1 $0
Q3 2022 Nov 10, 2022	BUY	$6.96 - $11.48 $974 - $1,607	140 Added 0.8%	17,548 $141,000
Q2 2022 Aug 12, 2022	SELL	$5.68 - $15.99 $7,054 - $19,859	-1,242 Reduced 6.66%	17,408 $122,000
Q1 2022 May 16, 2022	BUY	$13.16 - $22.64 $48,455 - $83,360	3,682 Added 24.6%	18,650 $282,000
Q4 2021 Feb 14, 2022	BUY	$19.56 - $32.94 $117,809 - $198,397	6,023 Added 67.33%	14,968 $329,000
Q3 2021 Nov 12, 2021	BUY	$22.73 - $36.04 $203,319 - $322,377	8,945 New	8,945 $241,000

Others Institutions Holding FDMT

# of Institutions

144

Shares Held

56.9M

Call Options Held

137K

Put Options Held

111K

View Full List

About 4D Molecular Therapeutics, Inc.

Ticker FDMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,382,400
Market Cap $195M
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...

More about FDMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account